Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Schizophrenia - aripiprazole: review decison - July 2011 information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 76 KB)

Review Proposal - May 2011 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 60 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 123 KB)

TA213 Schizophrenia - aripiprazole: press release information

Download PDF version information

Schizophrenia - aripiprazole: equality impact assessment 

Schizophrenia - aripiprazole: final appraisal determination information

Schizophrenia - aripiprazole: final appraisal determination guidance

Schizophrenia - aripiprazole: final appraisal determination guidance (PDF 219 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 149 KB)

Consultee and commentator comments on the Appraisal Consultation Document

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): covering letter

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): covering letter (PDF 60 KB)

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): response

Bristol Myers Squibb (also on behalf of Otsuka Pharmaceuticals): response (PDF 338 KB)

Royal College of Paediatrics and Child Health

Royal College of Paediatrics and Child Health (PDF 19 KB)

Comments on the Appraisal Consultation Document received through the NICE website

Aripiprazole for the treatment of schizophrenia in people aged 15-17: appraisal consultation

Schizophrenia - aripiprazole: appraisal consultation document information

Schizophrenia - aripiprazole: evaluation report

Schizophrenia - aripiprazole: pre-meeting brief

Schizophrenia - aripiprazole: pre-meeting brief (PDF 203 KB)

Schizophrenia - aripiprazole: Evidence Review Group report

Schizophrenia - aripiprazole: Evidence Review Group report (PDF 770 KB)

Schizophrenia - aripiprazole: Evidence Review Group report addendum

Schizophrenia - aripiprazole: Evidence Review Group report addendum (PDF 131 KB)

Schizophrenia - aripiprazole: manufacturer submission

Schizophrenia - aripiprazole: manufacturer submission (PDF 1.87 MB)

Schizophrenia - aripiprazole: NICE clarification letter

Schizophrenia - aripiprazole: NICE clarification letter (PDF 29 KB)

Schizophrenia - aripiprazole: manufacturer response to clarification letter

Schizophrenia - aripiprazole: manufacturer response to clarification letter (PDF 243 KB)

Schizophrenia - aripiprazole: non-manufacturer submissions

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Nursing

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Nursing (PDF 30 KB)

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Paediatrics and Child Health

Schizophrenia - aripiprazole: manufacturer submission - Royal College of Paediatrics and Child Health (PDF 27 KB)

Schizophrenia - aripiprazole: expert written personal statements

Schizophrenia - aripiprazole: expert written personal statements - Lamb

Schizophrenia - aripiprazole: expert written personal statements - Lamb (PDF 150 KB)

Schizophrenia - aripiprazole: expert written personal statements - McDougall

Schizophrenia - aripiprazole: expert written personal statements - McDougall (PDF 20 KB)

Schizophrenia - aripiprazole: expert written personal statements - Antoniou

Schizophrenia - aripiprazole: expert written personal statements - Antoniou (PDF 38 KB)

Schizophrenia - aripiprazole: expert written personal statements - Travis

Schizophrenia - aripiprazole: provisional matrix

Schizophrenia - aripiprazole: draft scope